- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07619703
Effects of a Neurorehabilitation Program Based on CIMT and Non-invasive Neuromodulation Through C-tDCS on the Recovery of Paretic Upper Limb Function, Quality of Life, and Therapeutic Alliance in Women From the Araucanía Region Who Suffered a Stroke (CIMT + tDCS). ((CIMT - tDCS))
Effects of a Neurorehabilitation Program Based on Constraint-Induced Movement Therapy (CIMT) and Non-invasive Neuromodulation Through Cerebellar Transcranial Direct Current Stimulation (C-tDCS) on the Recovery of Paretic Upper Limb Function, Quality of Life, and Therapeutic Alliance in Women From the Araucanía Region Who Suffered a Stroke.
Studie Overzicht
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Arlette Doussoulin, PhD
- Telefoonnummer: +56997445912
- E-mail: arlette.doussoulin@ufrontera.cl
Studie Locaties
-
-
Araucania
-
Temuco, Araucania, Chili, 4780000
- Werving
- Universidad de La Frontera, Temuco, Chile.
-
Contact:
- Arlette Doussoulin, Phd Human Motricity
- Telefoonnummer: 997445912
- E-mail: arlette.doussoulin@ufrontera.cl
-
Onderonderzoeker:
- Ornella Bahamondes, Msc
-
Onderonderzoeker:
- Mauro Obreque, Msc
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Women aged between 30 and 80 years.
- Who present hemorrhagic or ischemic stroke confirmed by CT with evolution greater than 1 month, corroborated by discharge epicrisis supporting the diagnosis of the patient.
- Who presents trunk control in sitting.
- Score greater than 14 points on the Minimental Examination scale.
- Function of the upper extremity, referring to taking and releasing a small ball with the affected hand and signing or accepting the consent written informed.
Exclusion Criteria:
- Shoulder pain greater than 4 according to the VAS scale and spasticity greater than 2 according to the Modified Ashworth Scale.
- Sensory compromise (visual-auditory).
- Presence of severe aphasia.
- Cochlear implants, aneurysm clips, brain electrodes and cardiac pacemaker.
- Epilepsy or psychiatric disorders (diagnosed in the last 3 months).
- Pregnancy, use of psychotropic medications.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CIMTm y ctDCS
c-tDCS will be applied during the first 20 minutes of the session simultaneously with the practice of motor tasks of specific movements aimed at the upper extremity, continuing the session with 100 minutes of CIMTm.
|
Intervention: The protocol will be carried out in a total of 10 sessions, with a daily frequency over a period of 2 weeks. Experimental group: The c-tDCS will be applied for the first 20 minutes, along with the performance of the first motor tasks associated with CIMTm. To do this, a direct current of between 1.5 to 2 mA will be used in the right cerebellar hemisphere. The CIMTm will be implemented with a duration of 120 minutes and consists of 3 components: repetitive task training, use of a glove on the healthy hand and behavioral transfer package. Control group: The electrodes will be located in the same position of the EG, but simulated stimulation (sham) will be used, which will consist of the application of an initial current that will be maintained for one minute with a 30-second ramp until reaching 1.5 mA and a 30-second descending ramp, after which the device will turn off (program available on the equipment). The CIMTm session is the same as the experimental group.
Andere namen:
|
|
Sham-vergelijker: CIMTm y ctDCS sham
c-tDCS (sham) will be used, which will consist of the application of an initial current that will be maintained for one minute with a 30-second ramp until reaching 1.5 mA and a 30-second descending ramp, after which the device will turn off (program available on the device).
|
Intervention: The protocol will be carried out in a total of 10 sessions, with a daily frequency over a period of 2 weeks. Experimental group: The c-tDCS will be applied for the first 20 minutes, along with the performance of the first motor tasks associated with CIMTm. To do this, a direct current of between 1.5 to 2 mA will be used in the right cerebellar hemisphere. The CIMTm will be implemented with a duration of 120 minutes and consists of 3 components: repetitive task training, use of a glove on the healthy hand and behavioral transfer package. Control group: The electrodes will be located in the same position of the EG, but simulated stimulation (sham) will be used, which will consist of the application of an initial current that will be maintained for one minute with a 30-second ramp until reaching 1.5 mA and a 30-second descending ramp, after which the device will turn off (program available on the equipment). The CIMTm session is the same as the experimental group.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Effects of CIMTm combined with c-tDCS on paretic upper extremity function in women with stroke.
Tijdsspanne: From enrollment to the end of treatment at 8 weeks.
|
Evaluated through the Action Research Arm Test (pre- and post-treatment): scale that evaluates both arms in order to obtain a total description of the function of the upper extremity, after a cortical injury.
It is made up of 19 items grouped into 4 subtests: grip, grasp, clamp, gross movement.
All items are evaluated on a 4-point scale from 0 (no movement) to 3 (normal movement).
This measure has been widely validated in Spanish-American speaking countries, thereby obtaining its degree of reliability and instrumental validity.
The reliability analysis using Cronbach's alpha obtained in the studies was 0.96, indicating high internal consistency.
|
From enrollment to the end of treatment at 8 weeks.
|
|
Effects of CIMTm combined with c-tDCS on paretic upper extremity function in women with stroke.
Tijdsspanne: From enrollment to the end of treatment at 4 weeks.
|
Evaluated through the Action Research Arm Test (pre-postreatment), a scale that evaluates both arms in order to obtain a total description of the function of the upper extremity, after a cortical injury.
It is made up of 19 items grouped into 4 subtests: grip, grasp, clamp, gross movement.
All items are evaluated on a 4-point scale from 0 (no movement) to 3 (normal movement).
This measure has been widely validated in Spanish-American speaking countries, thereby obtaining its degree of reliability and instrumental validity.
The reliability analysis using Cronbach's alpha obtained in the studies was 0.96, indicating high internal consistency.
|
From enrollment to the end of treatment at 4 weeks.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Hartinfarct
- Therapeutica
- Gedragsdisciplines en activiteiten
- Elektrische stimulatietherapie
- Convulsieve therapie
- Psychiatrische somatische therapieën
- Electroshock
- Psychologische technieken
- Transcraniale directe stroomstimulatie
Andere studie-ID-nummers
- Universidad de La Frontera
- CIMT + ctDCS (Andere identificatie: Universidad de La Frontera)
- CIMTm + ctDCS (Andere identificatie: Red Neuroaraucanía Chile)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .